DexCom, Inc. (NASDAQ:DXCM) Given Average Rating of “Moderate Buy” by Brokerages

Shares of DexCom, Inc. (NASDAQ:DXCM) have been given a consensus rating of “Moderate Buy” by the eighteen research firms that are presently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation, twelve have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $99.29.

A number of research analysts recently issued reports on the stock. Sanford C. Bernstein boosted their target price on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Canaccord Genuity Group raised their target price on DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Royal Bank of Canada decreased their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Finally, Wells Fargo & Company upped their price objective on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $86.83 on Friday. The company has a 50 day simple moving average of $80.77 and a two-hundred day simple moving average of $76.21. The stock has a market cap of $33.92 billion, a price-to-earnings ratio of 51.99, a PEG ratio of 2.22 and a beta of 1.12. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom has a 12 month low of $62.34 and a 12 month high of $142.00.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 42,342 shares of company stock valued at $3,628,069. 0.30% of the stock is owned by insiders.

Institutional Trading of DexCom

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its position in DexCom by 2.2% during the third quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock worth $664,056,000 after purchasing an additional 214,136 shares during the last quarter. Jennison Associates LLC grew its stake in shares of DexCom by 10.3% in the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after buying an additional 710,858 shares during the period. Groupama Asset Managment increased its holdings in shares of DexCom by 1.1% during the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock worth $1,912,000 after buying an additional 31,358 shares during the last quarter. Westfield Capital Management Co. LP raised its position in shares of DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after buying an additional 876,739 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in DexCom by 11.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock valued at $183,298,000 after acquiring an additional 288,381 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.